Publications by authors named "Chrystelle Francois"
Article Synopsis
- Susac syndrome is a rare disease primarily affecting young women, characterized by occlusive microvessel issues in the brain, retina, and inner ear, and lacks established treatment protocols from randomized trials.
- The study investigated the effectiveness of glucocorticoids alone or with other immunosuppressive treatments for preventing relapses in Susac syndrome, and involves a national cohort of patients recruited in France since 2011.
- Data were collected on various health indicators and treatments over a 36-month period to determine the first relapse, involving 64 patients, and the study is registered on ClinicalTrials.gov for transparency.
Article Synopsis
- Nonreversible hearing loss (HL) is a significant issue for patients with Susac syndrome (SuS), prompting a study to identify risk factors associated with HL in these individuals.* -
- The CARESS study involved 36 patients diagnosed with SuS, revealing that 52.8% experienced severe HL after a median follow-up of about 52 months, with many showing cochleovestibular involvement at diagnosis.* -
- The study concluded that the use of immunosuppressive (IS) drugs at diagnosis may lower the odds of developing severe HL, suggesting these drugs should be regularly considered in SuS treatment.*
Objective: To evaluate the specific response of SLE patients to BNT162b2 vaccination and its impact on autoimmunity defined as in vivo production of interferon-alpha (IFNα) by plasmacytoid dendritic cells (pDCs) and autoreactive immune responses.
Methods: Our prospective study included SLE patients and healthy volunteers (HV) who received 2 doses of BNT162b2 vaccine 4 weeks apart. Subjects under immunosuppressive drugs or with evidence of prior COVID-19 were excluded.
Systemic lupus erythematosus (SLE) patients are at risk for pneumococcal infection. Twenty-one consecutive SLE patients (40[25-75] years) received the sequential PCV13/PPSV23 vaccine and factors associated with long-term protection were analyzed. Immune protection, defined by an antigen-specific IgG concentration ≥1.
View Article and Find Full Text PDF